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ABSTRACT 25 
Medication related osteonecrosis of the jaw (MRONJ) is a complex disease which can be 26 
associated with multiple morbidities and is challenging to treat. This review evaluates the 27 
literature on the role and efficacy of Teriparatide (TPTD) as a treatment for MRONJ. The 28 
clinical, radiological, histopathological and serological parameters used to assess treatment 29 
response have been described. Electronic databases were searched to retrieve articles (April 30 
2005 and April 2020) based on a strict inclusion criterion. 17 articles were included in this 31 
review. Of the 91 patients treated; only 6 received TPTD as a standalone treatment. There 32 
were significant variations in defining treatment outcomes and measuring treatment 33 
response. The longest follow-up period was 26 months, and twelve studies failed to report 34 
follow up.  The overall quality of evidence is weak with potential for a high risk of bias, making 35 
it difficult to determine the efficacy of TPTD and its long-term effects. However, TPTD may 36 
play a role for treatment of intractable MRONJ in osteoporotic patients or those unfit for 37 
surgery. Therefore, randomised clinical trials on larger patient cohorts with long term follow 38 
up is required to confirm efficacy, safety and inform treatment indications for TPTD in the 39 
treatment of MRONJ.  40 
 41 
INTRODUCTION 42 
The American Association for Oral and Maxillofacial Surgeons (AAOMS)1 defines medication-43 
related osteonecrosis of the jaw (MRONJ) if all the following criteria are met: 44 
1) Current or previous treatment with antiresorptive or antiangiogenic agents. 45 
2) Exposed bone or bone that can be probed through an intraoral or extraoral fistula(e) in 46 
the maxillofacial region that has persisted for more than eight weeks.  47 
3) No history of radiation therapy to the jaws or obvious metastatic disease to the jaws. 48 
MRONJ was first documented in 2003 2 . Initially, it was known as bisphosphonate related 49 
osteonecrosis of the jaw (BRONJ) because it was exclusively associated with patients taking 50 
bisphosphonates. Bisphosphonates are used in various conditions including the treatment of 51 
osteoporosis, hypercalcaemia in metastatic breast cancer and multiple myeloma. However, 52 
other antiresorptive medications such as denosumab and angiogenesis inhibitors have since 53 
been identified as causing osteonecrosis of the jaw, hence the term MRONJ was coined1.  54 
MRONJ can occur as a result of an insult such as dental treatment (e.g. extractions) or 55 
spontaneously. Despite it being relatively uncommon, it can affect up to 0.01% of patients 56 
receiving oral bisphosphonates, 12% of patients receiving intravenous bisphosphonates, and 57 
16% in patients receiving a combination of bisphosphonates and antiangiogenics1.  58 
Interventions used to treat this complication are diverse, controversial and largely empirical 59 
hence the drive for preventative measures. In aggressive cases, MRONJ does not always 60 
respond to routine treatments and may persist or progress to an advanced stage making it 61 
challenging to treat. AAOMS outlines treatment strategies based on the stage of MRONJ 1. The 62 
failure of conventional treatment strategies has led to research into more novel ways of treating 63 
MRONJ, including hyperbaric oxygen therapy, platelet rich plasma, low-level laser irradiation, 64 
bone morphogenic protein and the use of recombinant parathyroid hormone (PTH)1. 65 
Harper et al.3 (2007) reported the first case in which Teriparatide (TPTD) was successfully used 66 
to treat BRONJ. Since then, there have been multiple publications on the use of TPTD for the 67 
treatment of MRONJ, and the International Task Force on Osteonecrosis of the Jaw currently 68 
considers TPTD as an option for treatment of MRONJ in osteoporotic patients4. TPTD is a 69 
molecule that makes up the first 34 amino acids (recombinant 1-34 N-terminal sequence) of the 70 
intact PTH5. It is involved in the stimulation of osteoblasts to promote bone formation, and 71 
subsequently osteoclasts for bone resorption, thereby regulating bone remodelling 6 . 72 
Depending on the duration and dose administered, TPTD can have both anabolic and catabolic 73 
effects on bone, by either stimulating new bone formation or dissolving calcium from bone. 74 
TPTD is able to reverse the anti-resorptive effects of bisphosphonates by promoting the activity 75 
of osteoblasts and enhancing the metabolic function of osteoclasts. In the UK, it is the second-76 
line treatment for osteoporosis and the only licensed anabolic treatment for osteoporosis in 77 
many other countries5.  78 
The primary aim of this study is to review the existing scientific literature to evaluate the role 79 
and efficacy of TPTD as a treatment modality for MRONJ. We will describe the clinical, 80 
radiological, histopathological and serological parameters used to assess the treatment 81 
response of TPTD as either a stand-alone treatment or as part of multi-therapy regime.  82 
  83 
MATERIALS AND METHODS  84 
Electronic databases search in Pubmed, Embase via OVID and Scopus was conducted to retrieve 85 
articles published in the English language between April 2005 and April 2020. The time period 86 
was chosen as the first reported case of TPTD use for MRONJ management was described in 87 
20073.  88 
The search strategy was jointly developed by the authorship team in collaboration with a 89 
medical information specialist (Librarian from University of Sheffield, UK). Tailored search 90 
strings containing keywords and database-specific medical subject headings (MeSH) for the two 91 
major topics (MRONJ treatment and TPTD) were developed. Multiple variations of search terms 92 
were combined to produce different sets of results and the final search strategy was pilot-tested 93 
and modified accordingly. The final search including the following terms: “MRONJ” OR 94 
“medication related osteonecrosis” OR “BRONJ” OR “bisphosphonate related osteonecrosis” 95 
AND “teriparatide” OR “recombinant parathyroid hormone” AND “management” OR 96 
“treatment”. In addition to the electronic searches, grey literature and reference lists of 97 
selected articles were screened for relevant studies that may not have been identified through 98 
the electronic search.  99 
Article citations were exported to EndNote® reference manager software (Clarivate Analytics, 100 
Philadelphia, USA) and duplicates were removed. The first screen based on analysis of title and 101 
abstract was conducted by the two independent reviewers and any articles deemed not 102 
relevant were removed. The second screen involved detailed examination of full-text articles 103 
against the eligibility criteria by the same two reviewers. The shortlists were compared, and 104 
differences discussed, obtaining a final selection of studies. 105 
The inclusion criteria were studies which looked at the use of TPTD for management/treatment 106 
of MRONJ/BRONJ in human subjects. Only articles published in the English language in indexed 107 
peer-reviewed journals were included. Abstracts, letters to the editor, commentaries, animal 108 
studies and those which focussed on the treatment of osteoradionecrosis with TPTD were 109 
excluded.  110 
Relevant data from selected articles were extracted, processed and tabulated into a pre-111 
developed data collection form in Microsoft Excel® (Microsoft Corporation, Washington, USA) 112 
by three reviewers. The following information was recorded:  113 
● Study details (authors, year and country of publication, aims) 114 
● Study methods (design, sample size and selection)  115 
● Patient details (demographics, cause of MRONJ including details of relevant 116 
medications, whether MRONJ-related medication was continued whilst being treated 117 
with TPTD) 118 
● MRONJ diagnosis (site and size, clinical staging, duration of osteonecrosis prior to TPTD 119 
treatment) 120 
● TPTD (dose, route, stand-alone or multi-therapy, duration of treatment, side-effects, 121 
follow-up period)   122 
● Treatment response (clinical, radiological, histopathological and serological outcome 123 
measures) 124 
● Description of outcome variables (no improvement, partial healing, complete 125 
resolution or worsened disease) 126 
 127 
RESULTS 128 
The electronic search identified 103 records. In addition, one article was identified through 129 
citation searching. Fifty-nine duplicates were removed. After the first screen based on analysis 130 
of titles and abstracts, 20 articles did not satisfy the inclusion criteria and were excluded. A full 131 
text examination of the remaining 24 articles excluded a further 7 articles, resulting in 17 132 
articles for inclusion in this review paper.  133 
A narrative synthesis of the main study findings is presented in Table 1. The 17 selected articles 134 
consisted of nine case reports3,7 ,8 ,9 ,10 ,11 , 12 ,13 ,14, two case series15 ,16, two comparative pilot 135 
studies 17 , 18 , a retrospective longitudinal study
19 , a retrospective multicentre study 20 , a 136 
prospective preliminary study21 and a prospective interventional study22.   137 
Across all studies, there were a total of 94 MRONJ patients initially treated with TPTD (mean 138 
age 76 years). However, as three patients dropped out of TPTD treatment early, treatment 139 
outcomes were only reported in 91 patients. More than 50% of patients were female, although 140 
it was not possible to provide an exact breakdown as gender was not uniformly reported across 141 
all studies. Most patients (n=88) were taking oral bisphosphonates which included alendronate, 142 
risedronate, ibandronate, pamidronate or minodronate, and in some cases, more than one of 143 
these medications was being taken. The remaining patients (n=6) were taking intravenous (IV) 144 
antiresorptive medications including zoledronate (n=2) and Denosumab (n=2). The IV  145 
medication name was not specified in two patients19,20. The antiresorptive medications were 146 
mostly taken for treatment of primary or secondary osteoporosis. In three articles the reason 147 
for taking bisphosphonates had not been stated15,15166,20. The shortest duration a patient had 148 
been taking an oral bisphosphonate before developing MRONJ was six months21; this 149 
information had not been reported for patients taking IV antiresorptives.  150 
Some studies reported spontaneous development of MRONJ, but in most cases a surgical, 151 
traumatic or infective aetiology was reported. These included extractions, endodontic 152 
treatment, implant surgery, traumatic prosthesis and periodontitis. In four studies the cause of 153 
MRONJ was not documented8,15,1516,21 MRONJ predominantly occurred in the mandible (n=68) 154 
followed by the maxilla (n=15) which included the unusual site of the palatal torus13 and in a 155 
few patients both jaws were affected (n=5)22.  In some patients the clinical site had not been 156 
specified (n=6). The osteonecrosis defect size had not been reported in any studies, but the 157 
clinical staging had been documented in most cases. The AAOMS1 classification was most 158 
frequently used except Pelaz et al.17 used the  Ruggiero classification (2006)23 and Morishita et 159 
al.20 staged according to the classification outlined in the Position Paper (2017) of the Japanese 160 
Allied Committee on Osteonecrosis of the Jaw24 (Table 1). Harper et al.3 did not provide any 161 
information on clinical staging and Kwon et al.15 did not mention the staging system used. Doh 162 
et al.9 used AAOMS treatment recommendations although the actual clinical staging was not 163 
stated. Most patients were diagnosed with either stage 2 or 3 MRONJ, except for one patient 164 
who was diagnosed with stage 120. In the case of studies where the clinical staging was not 165 
mentioned, based on the reported clinical descriptions they were classified according to the 166 
AAOMS guidelines. Where specified ,the time from MRONJ diagnosis to the time of staring TPTD 167 
treatment ranged between 2 to 26 months3,7,9,10,11,12,13,14,15. 168 
The dose and frequencies of TPTD treatment varied, as some were taken daily and others at 169 
weekly or monthly intervals. As documented in table 1, in eleven studies TPTD was administered 170 
daily at a dose of 20μg subcutaneously. In four studies TPDP was administered weekly at a dose 171 
of 56.5μg. Yoshiga et al. (2013)16  prescribed daily TPDP for one patient and weekly for the other. 172 
There are only three studies1615,17,1917 in which TPTD can be strictly described as a stand-alone 173 
treatment, since they were not receiving any other intervention at the time of taking TPTD. One 174 
study compared the efficacy of daily versus weekly TPTD injections8. A further study compared 175 
MRONJ treatment using TPTD and plasma rich growth factors, producing better results with the 176 
latter treatment17. The longest duration of treatment with TPTD was a period of 26 months,20,22 177 
It was highlighted that TPTD treatment should not be taken for longer than two years duration 178 
due to the risk of osteosarcoma5.  179 
In twelve studies the antiresorptive treatment was stopped prior to starting TPTD, although five 180 
studies do not specify whether antiresorptive treatment had been stopped or not10,11,17,18,19. 181 
Amongst the studies where antiresorptive medications were stopped, six studies did not specify 182 
the cessation period before starting TPTD, three studies reported a cessation period between 183 
three and twelve months 3,14,16 and the other three studies indicated that TPTD was started 184 
immediately after cessation of the antiresorptive treatment 8,12,13 In one study, for patients to 185 
be included in the study they needed to “continue osteoporosis treatment”18, although the 186 
details regarding this are not clearly specified. Follow up on completion of TPTD ranged from 6-187 
24 months7,8,9,17,19,17. The majority of studies do not document any follow up on completion of 188 
TPTD treatment.   189 
The treatment response to TPTD was assessed using clinical, radiological, histological and 190 
biochemical markers (BCM) including bone turnover markers (BTM). Details of these methods 191 
are provided in Tables 2,3, and 4 and the results of each will be presented.  192 
 193 
Clinical treatment measures 194 
Across the studies, clinical improvement was seen in 32 patients (35%), complete resolution in 195 
50 patients (55%), no improvement in 2 patients (2%)17,22, stable disease in 6 patients (7%)20 196 
and worsening of disease in 1 patient20 (1%).  197 
 Clinical outcomes measures included: improvements in pain, neurosensory disturbance, 198 
absence of pus, discharge or infection, healing of fistula, reducing area of bone exposure and 199 
movement of associated pathological fracture. In some cases, spontaneous exfoliation of the 200 
sequestrum has been reported as a favourable clinical outcome.  201 
In three articles17,1917,20, the authors have stated how they stratified the clinical treatment 202 
outcome.  Kim et al. (2014)19 measured treatment outcome based on the improvement of 203 
BRONJ stage and the evolution of the disease after 6 months of treatment which was stratified 204 
as: “No improvement” (no improvement or worsening of BRONJ status), “Moderate 205 
improvement” (one stage of improvement of BRONJ status), “Marked improvement” 206 
(improvement of two stages of BRONJ or complete healing). Pelaz et al. (2014)17 defined 207 
treatment success if there was clinical evidence of healing or symptomatic/asymptomatic bone 208 
exposure. Morishita et al. (2020)20 defined treatment outcomes according to the following 209 
criteria: “complete resolution”(the disappearance of all objective symptoms for at least 3 210 
months), “improvement” (the down-staging of MRONJ for at least 3 months), “stable disease” 211 
(no change in the stage of MRONJ during the observation) and “exacerbation” (up-staging of 212 
MRONJ during the observation). The treatment was defined as “effective” in the cases of 213 
“complete resolution” and “improvement”, and “no response” in the cases of “stable disease” 214 
and “exacerbation” based on above clinical findings on the last observation day. 215 
 216 
Radiographic treatment measures   217 
Ohbayashi et al. (2013)8 demonstrated remarkable bone regeneration on the CT scan six 218 
months after starting TPTD treatment and bone scintigraphy showed regression of the uptake 219 
area. Kakehashi et al. (2015)22 reported partial improvement in one patient from their study 220 
and assessment of dual-energy x-ray absorptiometry (DXA) scanning and BTM revealed that this 221 
patient did not show any improvement in the bone mineral quantity in either the spine or 222 
femoral areas. Jung et al. (2017)21 used cone beam computed tomography (CBCT) scans to 223 
compare between treatment groups by measuring the bone regeneration ratio and comparing 224 
it by superimposition of CBCT scans, acquired immediately post-operation and after 6 months. 225 
For standardisation they considered bone tissue as having 350 to 3000 pixels of the Hounsfield 226 
unit. 227 
In addition to clinical and serological outcome modalities Ohbayashi et al. (2020)18 utilised 228 
various imaging techniques (Table 4) to assess the response of treatment.  Bone metabolism 229 
was measured by bone scintigraphy which was performed using a dual-head single-photon 230 
emission computerised tomography (SPECT)/CT) system. Unlike previous studies using SPECT in 231 
MRONJ25,26, the bone scintigraphy images were quantified using the bone uptake value (BUV), 232 
which was calculated as the bone accumulation of radiopharmaceuticals by correcting each 233 
pixel value of the bone scintigraphy. They calculated the BUV at baseline and six months 234 
following treatment for blinded assessment of the BUV.  235 
 236 
Serum treatment measures  237 
In eleven studies, serum markers were used to evaluate the response to TPTD treatment (Table 238 
2). Pelaz et al. (2014)17 measured baseline levels of alkaline phosphatase and calcium to rule 239 
out unexplained high levels prior to starting TPTD. These levels were monitored throughout 240 
treatment, however no further details were provided. Five studies showed a significant increase 241 
in BTM19921,13,1419, 21 over a variable range of 4-42 weeks. Kim et al. (2014)19 observed an obvious 242 
anabolic window, with earlier changes in OCN values and later increases in CTX values due to 243 
TPTD treatment. However, in other studies, there were variable results. For example, Kwon et 244 
al. (2012)15 reported a statistically significant increase (p = 0.006) in the s-OC values in all 245 
patients between values at baseline, two and three months. The S-CTX values also increased in 246 
four patients, whereas the remaining two patients showed minimal change, which was 247 
marginally significant (p = 0.018) between the mean values at baseline and 3 months. 248 
 249 
Ohbayashi et al. (2013)8 found significantly increasing bone formation and resorption markers 250 
except for uNTX at one month, but most markers except for BAP and TRACP-5b had decreased 251 
at nine months. However, all markers remained at a high level when compared with the 252 
baseline. While there was no significant difference in the percentage change between bone 253 
formation and bone resorption markers, variation in percentage change of each marker over 254 
time was statistically significant during TPTD administration. The authors recommended 255 
monitoring uric acid levels during treatment for assessment of adverse events.  256 
 257 
Yoshiga et al. (2013)16 found that the s-NTX level increased slightly in both patients they 258 
presented, but in the first patient serum P1NP level decreased after initiation of TPTD treatment 259 
whilst in the second patient serum P1NP level significantly increased 2 months after initiation 260 
of TPTD treatment . Kakehashi et al. (2015)22 reported a tendency for BAP and CTX to increase, 261 
however there was no statistically significant difference observed from baseline values. They 262 
concluded that BAP and CTX can not be used as predictive markers for the clinical outcome of 263 
TPTD therapy. Out of the serum markers utilised by Ohbayashi et al. (2020)18 (Table 4) only OC 264 
and P1NP were significantly different between both groups; OC and P1NP at 3 months of 265 
treatment, and P1NP at 6 months. Changes in BTM were noted less in the weekly TPTD group 266 
compared to the daily TPTD group, but the values were comparable at six months following the 267 
start of treatment.   268 
 269 
Doh et al. (2015)9 was the only study to document histological features in assessing the 270 
response to TPTD. Irregular reversal lines and active osteoblasts were noted adjacent to the 271 
lesion of necrotic bone indicating active bone remodelling. 272 
  273 
Prognostic treatment parameters 274 
Some studies looked at possible prognostic factors that can influence the result of TPTD 275 
treatment in MRONJ patients. Morishita et al. (2020)20 identified no prognostic factors for TPTD 276 
therapy. However, the oral administration of bisphosphonates might have a possibility for 277 
successful treatment outcomes with TPTD (p= 0.062). Jung et al. (2017)21 found that deep and 278 
narrow defects rapidly healed with regenerated new bone, rather than flat and shallow defects. 279 
Ohbayashi et al. (2013)8 suggested that P1NP level might be a good predictor of a positive 280 
prognosis of TPTD treatment. 281 
 282 
Kim et al. (2014)19 compared baseline parameters (age, BMI, duration of bisphosphonates usage, 283 
BTM, Vitamin D) between patients that had shown either moderate or marked improvement 284 
with TPTD treatment. Amongst these parameters, only baseline Vitamin D levels revealed a 285 
significant influence on the effect of TPTD. A multivariate analysis of various baseline 286 
parameters (age, BMI, duration of bisphosphonate usage, CTX, OCN) showed the difference in 287 
baseline Vitamin D levels to have remained significant (p=0.021) between both groups. 288 
However, this difference was not significant following adjustment of baseline PTH 289 
concentration. 290 
 291 
Complications and adverse side-effects 292 
Only three studies have documented complications related to TPTD treatment. Morishita et al. 293 
(2020)20 aimed for a 24 month course of TPTD treatment but five patients (17%) discontinued 294 
or interrupted treatment due to adverse side effects. They reported a patient who suffered 295 
from TPTD-induced arthritis which resulted in discontinuing treatment after 12 days. One 296 
patient experienced nausea and discontinued at 3 months and another patient experienced 297 
malaise and discontinued at 5 months. Treatment was interrupted due to inner stigma and renal 298 
dysfunction in two patients at  one month and two months, respectively.   299 
 300 
Two out of ten patients in the study conducted by Kakehashi et al. (2015)22 dropped out due to 301 
adverse side effects. These included facial and lower limb oedema, nausea, and vomiting in one 302 
patient which starting three days after starting TPTD, in addition to knee arthralgia in one 303 
further patient one week after administration. Pelaz et al. (2014)17 reported psychological 304 
problems in one out of four patients treated with TPTD. 305 
 306 
DISCUSSION   307 
With an increasing ageing population, Oral and Maxillofacial surgeons may see a greater 308 
proportion of patients exposed to antiresorptive medications27. These patients may present 309 
with multiple medical comorbidities and polypharmacy that may complicate the presentation 310 
and treatment options and render aggressive surgical treatment an unsuitable option.  311 
 312 
MRONJ is a complex disease process that can adversely affect quality of life28,29. It has a poorly 313 
understood pathophysiology1,2 with multiple hypothesises postulated to understand the 314 
mechanism of this disease affecting the jaw bones 30 , 31 . Theories include altered bone 315 
remodelling or over suppression of bone resorption3029,32, angiogenesis inhibition29,3130,32,33, 316 
constant microtrauma34, suppression of innate or acquired immunity 34 , 35 , vitamin D 317 
deficiency36, soft tissue bisphosphonate toxicity37, and inflammation or infection38,39,40. Most of 318 
this evidence based on animal models suggests the disease process to be multifactorial, 319 
contributing to the difficulty in developing effective targeted treatments.  320 
 321 
Current treatment strategies based on AAOMS guidance1  is stage-specific and ranges from 322 
conservative to surgical management, which has shown varying degrees of success in treating 323 
MRONJ. Conservative treatment including sequestrectomy and/or debridement has shown 324 
partial success with mucosal closure in 50% of cases, whereas more complex surgical 325 
treatments (i.e. resection) has shown healing success rate of 80%. However, the latter may not 326 
be a feasible option in some patients, particularly those with complex medical status, due to 327 
the associated surgical and anaesthetic risks of invasive surgery. This highlights the need for 328 
non-invasive therapeutics as an alternative or adjunctive treatment option.  329 
 330 
TPTD was approved by the US Food and Drug Administration agency in 2002 as the first 331 
osteoporosis therapy to stimulate bone formation in patients at high risk of bone fracture41. 332 
Abaloparatide, another PTH analogue, has since been approved by the FDA in 2017 also for 333 
severe osteoporosis42.  334 
 335 
This review highlights the lack of high-quality randomised evidence to assess the use of TPTD 336 
for MRONJ treatment, as the literature comprises mostly of case reports and case series (11 out 337 
of 17 studies). Whilst a clinical improvement has been demonstrated in a large proportion of 338 
patients, the relatively high success rate should be treated with caution since only six out of the 339 
91 patients received TPTD in isolation (Table 1). Amongst those receiving TPTD as part of a 340 
multi-therapy regime, there were a range of adjunctive treatments provided with ranged. There 341 
were also varying definitions and measurements of treatment outcomes, making it difficult to 342 
ascertain the efficacy of TPTD and whether the reported clinical improvements in MRONJ were 343 
related to TPTD alone or in combination with the other adjunctive treatments. Furthermore, 344 
twelve studies failed to report follow-up and in those which did, the follow-up period varied 345 
between 6 and 24 months. This makes it difficult to measure the long-term treatment outcomes 346 
and extent of adverse drug effects or complications.  347 
 348 
Variable outcome measures were reported (Table 4) of which the most important is the 349 
improvement in clinical signs and symptoms. However, imaging and serum markers can be 350 
useful adjuncts for diagnosis and assessment of treatment response. This review highlighted 351 
four possible prognostic parameters to predict a positive response to TPTD treatment. These 352 
included baseline Vitamin D levels, P1NP levels, deep and narrow bone defects and patients 353 
with oral bisphosphonates exposure as opposed to intravenous antiresorptive treatment. Most 354 
other reported serum markers have shown a significant change in response to TPTD treatment 355 
(Table 4). 356 
 357 
 The FDA43 have reported multiple adverse side-effects associated with  TPTD use. This review 358 
has shown effects including arthralgia, malaise, nausea, vomiting, renal impairment, and 359 
psychological problems in 8.5% of patients, which resulted in either discontinuation or 360 
interruption of treatment. The FDA43 have highlighted certain groups of patients in which TPTD 361 
is contraindicated: 362 
 363 
 Bone metastases and skeletal malignancies 364 
 Metabolic bone conditions  365 
 Hypercalcemia and Hypercalcaemic Disorders 366 
 Urolithiasis or Pre-existing Hypercalciuria  367 
 Orthostatic Hypotension  368 
 Drug Interactions (Digoxin) 369 
 Hypersensitivity  370 
 371 
In addition to the above, patients at risk of developing malignant bone tumours (Paget’s disease 372 
of bone, paediatric and young adult patients with open epiphyses, and patients with prior 373 
external beam or implant radiation involving the skeleton) should be treated with extreme 374 
caution due to the risk of developing osteosarcoma which has been associated with high 375 
exposure to TPTD. As this risk is dose and duration dependent, the FDA do not recommend the 376 
use of TPTD for longer than 24 months43. The findings from studies in this review showed that 377 
duration of TPTD treatment varied between 0.3 to 26 months due to certain factors including 378 
differences in study design, financial implications, adverse side-effects and early resolution of 379 
MRONJ. This risk highlights the importance of long-term follow-up, which unfortunately most 380 
of the studies have failed to report.  381 
 382 
TPTD treatment is under strict prescribing regulations under the UK’s NHS presumably due to 383 
the side effect profile and concerns related to risk of malignancy.  It is also associated with a 384 
high financial cost44 which should be take into consideration. 385 
 386 
 The available literature does not provide sufficient evidence to address our aim of determining 387 
the efficacy of TPTD treatment, mainly due to the lack of high-quality studies, control groups 388 
and randomisation. The overall quality of evidence is low and largely comprising isolated case 389 
reports, case series and small studies (largest study population of 29 patients) which increases 390 
the risk of bias in data interpretation and reporting. This review serves to highlight the need for 391 
further research and multicentre randomised-control trials to evaluate the efficacy of TPTD and 392 
treatment response on a bigger patient cohort to help inform its role in the management of 393 
MRONJ and provide guidance for adjunctive radiological, serological and histopathological 394 
measures of  tissue response.  395 
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